Mismatched clinicopathological response after concurrent chemoradiotherapy for thoracic esophageal cancer

3Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.
Get full text

Abstract

We have been treating patients with operable thoracic esophageal cancer according to our own protocol. It includes the initial concurrent chemoradiotherapy (CRT) followed by continuous CRT or surgery. Patients with good response to initial chemoradiotherapy were allowed to continue chemoradiotherapy, whereas the others were treated with surgery. However, there were two cases which showed discrepancies in the clinicopathological response. Both patients received initial chemoradiotherapy, including two courses of cisplatin (100-120 mg), 5-fluorouracil (750-1000 mg for 4 days) and radiation (44-50 Gy). On completion of the initial chemoradiotherapy, all diagnostic imaging modalities including barium swallow, esophagoscopy, endoscopic ultrasonography and thoracic computed tomography strongly implicated residual tumor with a reduction rate of 40-50%. The patients underwent radical esophagectomy 15-20 days after initial chemoradiotherapy. Pathological specimens only revealed thickening of the esophageal wall due to inflammatory change without residual carcinoma. These facts suggest the current limitations of diagnostic images in evaluating the response to chemoradiotherapy.

Cite

CITATION STYLE

APA

Okamoto, Y., Murakami, M., Kuroda, Y., Mizowaki, T., Nakajima, T., Kusumi, F., … Kobashi, Y. (2000). Mismatched clinicopathological response after concurrent chemoradiotherapy for thoracic esophageal cancer. Diseases of the Esophagus, 13(1), 80–86. https://doi.org/10.1046/j.1442-2050.2000.00084.x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free